[{"id":"067f213e-03a5-45b6-8ae7-e5474fb8a9c9","acronym":"C-906289-002","url":"https://clinicaltrials.gov/study/NCT05308264","created_at":"2025-02-25T20:13:27.067Z","updated_at":"2025-02-25T20:13:27.067Z","phase":"Phase 1/2","brief_title":"Study of R289 in Participants With Lower-risk Myelodysplastic Syndromes (LR MDS)","source_id_and_acronym":"NCT05308264 - C-906289-002","lead_sponsor":"Rigel Pharmaceuticals","biomarkers":" TNFA • CRP","pipe":" | ","alterations":" Chr del(5q)","tags":["TNFA • CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(5q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e R289"],"overall_status":"Recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 09/12/2022","start_date":" 09/12/2022","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2025-01-16"}]